Company intelligence / Profile preview

GTx

Memphis, Tennessee, United Statesnvidia.com ↗

Ownership: Private
Employees: ~68
Development stage: Commercial

Overview

GTx developed small molecule drugs targeting androgen and estrogen receptors for oncology and other indications. Its lead asset enobosarm failed in two Phase III trials for cancer cachexia in 2013; most other programs were discontinued or outlicensed. The company was acquired via reverse merger by Oncternal Therapeutics in June 2019.

Therapeutic areas: OncologyEndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Drug pipeline

8 assets

GTx-758

7 more assets in the full pipeline.

Request access →

Partnerships

Ipsen (toremifene development partnership—terminated)Merck & Co. ($400M SARM program deal—terminated)

Beyond the preview

Go deeper on GTx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTx.

Explore the full profile